H1N1 in allogeneic stem cell recipients: courses of infection and influence of vaccination on graft-versus-host-disease (GVHD)

(H1N1)v-like strain (X-179A)) vaccination formulated with the adjuvant system AS03 (Pandemrix™). Local and systemic events were generally mild and adjuvant vaccination was not associated with acute worsening of GVHD symptoms in 31 HSCT recipients suffering from limited (n=19) or extensive (n=12) chronic GVHD. Patients without chronic GVHD (n=24) did not develop de novo vaccine-related alloimmune phenomena within 3 months of post-interventional surveillance. Except one patient who got infected with H1N1 4 days after vaccination, none of the vaccinated subjects presented with signs of influenza manifestations in the sequel.